Lung cancer represents one of the most typical and deadliest cancers on the planet. Chimeric antigen receptor-T cell (CAR-T) therapy which might acknowledge antigens in a significant histocompatibility advanced (MHC)-independent method offers a brand new method for tumor remedy. However, lung cancer, as a stable tumor, faces a number of formidable obstacles to adoptive cell switch, which incorporates inhibition of T-cell localization and suppression of T-cell operate.
Therefore, lung cancer fails to reply considerably to infusions of CAR-T cells in most trials till now. PubMed was researched utilizing the phrases “CAR-T” and “lung cancer” solely in English from 2000 by June 2020. We additionally included outcomes offered in worldwide conferences, such because the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO).
Besides, we discovered new progress in CAR-T therapy for stable tumors as a complement. To improve the efficacy and conquer the restrictions, we collected some functions in lung cancer. In latest years, there have been some enhancements in choosing the right goal and lowering toxicity. CAR-T know-how offers a wonderful manner for tumor remedy, which doesn’t depend upon MHC molecules and offers a brand new technique for the utilization of tumor targets.
Targeting totally different antigens and overcoming the stable barrier, there are some enhancements in responding considerably and lowering toxicity. CAR-T know-how will play a decisive position within the remedy of lung cancer. Determining Schistosoma mansoni an infection fee and depth is difficult because of the low sensitivity of the Kato-Katz (KK) take a look at that underestimates the true illness prevalence.
Circulating cathodic antigen (CCA) excreted in urine is continually produced by grownup worms and has been used as the idea of a easy, non-invasive level of care take a look at (POC-CCA) for Schistosoma mansoni infections. Although the abundance of CCA in urine is proportional to worm burden, the POC-CCA take a look at is marketed as a qualitative take a look at, making it tough to research the wide selection of an infection intensities.
This research was designed to match the prevalence and depth of S. mansoni by KK and POC-CCA and quantify, on recent and frozen (<-20°C) urine samples, CCA utilizing the visible scores and the ESEquant LR3 reader.
Considerations for Assessment and Deployment of Rapid Antigen Tests for Diagnosis of Coronavirus Disease 2019
Diagnostic testing is a crucial instrument to mitigate the extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, however molecular testing capability stays restricted. Rapid diagnostic checks (RDTs) that detect SARS-CoV-2 protein antigens (Ag) provide the potential to considerably increase testing capability and to permit frequent, large-scale, inhabitants screening. Testing is straightforward, fast (outcomes typically accessible inside 15 minutes), and relevant for analysis at level of care.
However, implementation of Ag RDTs requires an in depth understanding of take a look at efficiency and operational traits in every testing state of affairs and inhabitants being evaluated. Successful implementation of Ag RDTs on a big scale ought to mix testing with technical oversight and with scientific and public well being infrastructure, and would require manufacturing at ranges a lot greater than presently potential.
In this commentary, we offer detailed issues for Ag RDT evaluation and use circumstances to encourage and allow broader manufacturing and deployment. The S. mansoni an infection charges inferred from POC-CCA and KK have been 40.7% and 9.4% respectively. Good correlations have been noticed between an infection intensities recorded by; i) the reader and visible scoring system on recent (Rho = 0.89) and frozen samples (Rho = 0.97), ii) the reader on recent urine samples and KK (epg) (Rho = 0.44).
Nevertheless, 238 POC-CCA optimistic kids have been unfavourable for KK, and sixteen of them had excessive ranges of CCA. The correlation between outcomes from the reader on recent and frozen samples was good (Rho = 0.85). On frozen samples, CCA was not detected in 55 samples that have been optimistic in recent urine samples.
A Biomimetic Aggregation-Induced Emission Photosensitizer with Antigen-Presenting and Hitchhiking Function for Lipid Droplet Targeted Photodynamic Immunotherapy
Photodynamic therapy (PDT) is a promising various method for efficient cancer remedy that’s related to an antitumor immune response. However, immunosuppression of the tumor microenvironment limits the immune response induced by PDT. Stimulation and proliferation of T cells is a crucial step for producing immune responses and is dependent upon the environment friendly presentation of tumor antigens and co-stimulatory molecules by antigen-presenting cells (APCs).
Here, biomimetic aggregation-induced emission (AIE) photosensitizers with antigen-presenting and hitchhiking skills (DC@AIEdots) are developed by coating dendritic cell (DC) membranes on the nanoaggregates of the AIEgens. Notably, the internal AIE molecules can selectively accumulate in lipid droplets of tumor cells, and the outer cell membrane can facilitate the hitchhiking of DC@AIEdots onto the endogenous T cells and improve the tumor supply effectivity by about 1.6 occasions.
Furthermore, DC@AIEdots can stimulate the in vivo proliferation and activation of T cells and set off the immune system. The potential functions of therapeutic brokers concentrating on lipid droplets for immunotherapy are indicated and a brand new hitchhiking method for drug supply is offered. Lastly, the research presents a photoactive and synthetic antigen-presenting platform for efficient T cell stimulation and cancer photodynamic immunotherapy.
Unusual aggregation property of recombinantly expressed cancer-testis antigens in mammalian cells
Transient expression of human intracellular proteins in human embryonic kidney (HEK) 293 cells is a dependable system for acquiring soluble proteins with biologically lively conformations. Contrary to standard ideas, we discovered that recombinantly expressed intracellular cancer-testis antigens (CTAs) confirmed frequent aggregation in HEK293 cells.
Although experimental subcellular localization of recombinant CTAs displayed correct cytosolic or nuclear localization, some proteins confirmed aggregated particles within the cell. This aggregative property was not noticed in recombinant housekeeping proteins.
BFP expression Adenovirus |
|||
AVP017 | GenTarget | 1x109 IFU/ml x 200ul | 418.8 EUR |
Description: pre-made BFP expression adenovirus, provided in DMEM medium. |
|||
Blunt E1 Expression Kit |
|||
abx098098-10rxns | Abbexa | 10 rxns | 560.4 EUR |
Blunt E2 Expression Kit |
|||
abx098873-10rxns | Abbexa | 10 rxns | 560.4 EUR |
RFP expression Adenovirus, in vivo ready |
|||
AVP001-PBS | GenTarget | 1x1011 IFU/ml x 50ul | 852 EUR |
Description: pre-made RFP expression adenovirus, provided in PBS solution. |
|||
CFP expression Adenovirus, in vivo ready |
|||
AVP002-PBS | GenTarget | 1x1011 IFU/ml x 50ul | 852 EUR |
Description: pre-made CFP expression adenovirus, provided in PBS solution. |
|||
GFP expression Adenovirus, in vivo ready |
|||
AVP011-PBS | GenTarget | 1x1011 IFU/ml x 50ul | 852 EUR |
Description: pre-made GFP expression adenovirus, provided in PBS solution. |
|||
YFP expression Adenovirus, in vivo ready |
|||
AVP012-PBS | GenTarget | 1x1011 IFU/ml x 50ul | 852 EUR |
Description: pre-made YFP expression adenovirus, provided in PBS solution. |
|||
BFP expression Adenovirus, in vivo ready |
|||
AVP017-PBS | GenTarget | 1x1011 IFU/ml x 50ul | 852 EUR |
Description: pre-made BFP expression adenovirus, provided in PBS solution. |
|||
Rac1 Expression Vector Set |
|||
STA-454 | Cell Biolabs | 1 kit | 1765.2 EUR |
Description: Rac1 Expression Vector Set contains 3 vectors: Rac wild type, T17N dominant negative mutant, and G12V constitutively active mutant. |
|||
RhoA Expression Vector Set |
|||
STA-456 | Cell Biolabs | 1 kit | 1765.2 EUR |
Description: RhoA Expression Vector Set contains 3 vectors: RhoA wild type, T19N dominant negative mutant, and G14V constitutively active mutant. |
|||
Cdc42 Expression Vector Set |
|||
STA-455 | Cell Biolabs | 1 kit | 1765.2 EUR |
Description: Cdc42 Expression Vector Set contains 3 vectors: Cdc42 wild type, T17N dominant negative mutant, and Q61L constitutively active mutant. |
|||
h ADA Expression Lentivirus |
|||
LVP923 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: ADA, containing a RFP-Blasticidin dual selection marker. |
|||
h IL6 Expression Lentivirus |
|||
LVP1144 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: HDAC1, containing a RFP-Blasticidin dual selection marker. |
|||
h CD4 Expression Lentivirus |
|||
LVP1152 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: CD4, containing a RFP-Blasticidin dual selection marker. |
|||
h IL4 Expression Lentivirus |
|||
LVP1161 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: IL4, containing a RFP-Blasticidin dual selection marker. |
|||
h IL7 Expression Lentivirus |
|||
LVP1162 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: IL7, containing a RFP-Blasticidin dual selection marker. |
|||
h KDR Expression Lentivirus |
|||
LVP1176 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: KDR, containing a RFP-Blasticidin dual selection marker. |
|||
h FAS Expression Lentivirus |
|||
LVP1181 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: FAS, containing a RFP-Blasticidin dual selection marker. |
|||
pAAV-MCS Expression Vector |
|||
VPK-410 | Cell Biolabs | 10 µg | 776.4 EUR |
Description: Clone your gene of interest into this AAV Expression Vector, then co-transfect along with AAV packaging vectors into a packaging host cell line such as 293AAV. |
|||
h OCT4 expression Adenovirus, in vivo ready |
|||
AVP013-PBS | GenTarget | 1x1011 IFU/ml x 50ul | 852 EUR |
Description: pre-made adenovirus express human stem cell factor, OCT4, provided in PBS solution for in vivo application. |
|||
h SOX2 expression Adenovirus, in vivo ready |
|||
AVP014-PBS | GenTarget | 1x1011 IFU/ml x 50ul | 852 EUR |
Description: pre-made adenovirus express human stem cell factor, SOX2, provided in PBS solution for in vivo application. |
|||
h OCT4 expression Adenovirus |
|||
AVP013 | GenTarget | 1x109 IFU/ml x 200ul | 418.8 EUR |
Description: pre-made adenovirus express human stem cell factor, OCT4, provided in DMEM medium. |
|||
h SOX2 expression Adenovirus |
|||
AVP014 | GenTarget | 1x109 IFU/ml x 50ul | 418.8 EUR |
Description: pre-made adenovirus express human stem cell factor, SOX2, provided in DMEM medium. |
|||
h CDR1 Expression Lentivirus |
|||
LVP917 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: CDR1, containing a RFP-Blasticidin dual selection marker. |
|||
h CD47 Expression Lentivirus |
|||
LVP918 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: CD47, containing a RFP-Blasticidin dual selection marker. |
|||
h ESR1 Expression Lentivirus |
|||
LVP924 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: ESR1, containing a RFP-Blasticidin dual selection marker. |
|||
r Syn1 Expression Lentivirus |
|||
LVP925 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for rat target: Syn1, containing a RFP-Blasticidin dual selection marker. |
|||
h NME4 Expression Lentivirus |
|||
LVP932 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: NME4, containing a RFP-Blasticidin dual selection marker. |
|||
h EGFR Expression Lentivirus |
|||
LVP1142 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: EGFR, containing a RFP-Blasticidin dual selection marker. |
|||
h NRP1 Expression Lentivirus |
|||
LVP1145 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: HDAC1, containing a RFP-Blasticidin dual selection marker. |
|||
h MUC1 Expression Lentivirus |
|||
LVP1148 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: HDAC1, containing a RFP-Blasticidin dual selection marker. |
|||
h CD8a Expression Lentivirus |
|||
LVP1151 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: CD8a, containing a RFP-Blasticidin dual selection marker. |
|||
h PIGF Expression Lentivirus |
|||
LVP1154 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: PIGF, containing a RFP-Blasticidin dual selection marker. |
|||
h BRAF Expression Lentivirus |
|||
LVP1156 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: BRAF, containing a RFP-Blasticidin dual selection marker. |
|||
h ROS1 Expression Lentivirus |
|||
LVP1158 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: ROS1, containing a RFP-Blasticidin dual selection marker. |
|||
h CD3E Expression Lentivirus |
|||
LVP1163 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: IL7, containing a RFP-Blasticidin dual selection marker. |
|||
h KLK3 Expression Lentivirus |
|||
LVP1171 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: KLK3, containing a RFP-Blasticidin dual selection marker. |
|||
h NEK6 Expression Lentivirus |
|||
LVP1182 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: NEK6, containing a RFP-Blasticidin dual selection marker. |
|||
h NEK7 Expression Lentivirus |
|||
LVP1183 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: NEK7, containing a RFP-Blasticidin dual selection marker. |
|||
h LIN28 expression Adenovirus, in vivo ready |
|||
AVP015-PBS | GenTarget | 1x1011 IFU/ml x 50ul | 852 EUR |
Description: pre-made adenovirus express human stem cell factor, LIN28, provided in PBS solution for in vivo application. |
|||
h LIN28 expression Adenovirus |
|||
AVP015 | GenTarget | 1x109 IFU/ml x 200ul | 418.8 EUR |
Description: pre-made adenovirus express human stem cell factor, LIN28, provided in DMEM medium. |
|||
h GPNMB Expression Lentivirus |
|||
LVP921 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: GPNMB, containing a RFP-Blasticidin dual selection marker. |
|||
h DECR1 Expression Lentivirus |
|||
LVP927 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: DECR1, containing a RFP-Blasticidin dual selection marker. |
|||
h DECR2 Expression Lentivirus |
|||
LVP928 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: DECR2, containing a RFP-Blasticidin dual selection marker. |
|||
h NMRK1 Expression Lentivirus |
|||
LVP930 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: NMRK1, containing a RFP-Blasticidin dual selection marker. |
|||
h PITX3 Expression Lentivirus |
|||
LVP931 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: PITX3, containing a RFP-Blasticidin dual selection marker. |
|||
h HDAC1 Expression Lentivirus |
|||
LVP1143 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: HDAC1, containing a RFP-Blasticidin dual selection marker. |
|||
h VEGFB Expression Lentivirus |
|||
LVP1146 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: HDAC1, containing a RFP-Blasticidin dual selection marker. |
|||
h PARP1 Expression Lentivirus |
|||
LVP1149 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: HDAC1, containing a RFP-Blasticidin dual selection marker. |
|||
h IL3RA Expression Lentivirus |
|||
LVP1150 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: IL3RA, containing a RFP-Blasticidin dual selection marker. |
|||
h PTCH1 Expression Lentivirus |
|||
LVP1155 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: PTCH1, containing a RFP-Blasticidin dual selection marker. |
|||
h SART3 Expression Lentivirus |
|||
LVP1159 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: SART3, containing a RFP-Blasticidin dual selection marker. |
|||
h TIGIT Expression Lentivirus |
|||
LVP1160 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: TIGIT, containing a RFP-Blasticidin dual selection marker. |
|||
h EDNRA Expression Lentivirus |
|||
LVP1165 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: EDNRA containing a RFP-Blasticidin dual selection marker. |
|||
h Foxp3 Expression Lentivirus |
|||
LVP1172 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: Foxp3, containing a RFP-Blasticidin dual selection marker. |
|||
m RIKEN Expression Lentivirus |
|||
LVP1174 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for mouse target: RIKEN, containing a RFP-Blasticidin dual selection marker. |
|||
h APLP2 Expression Lentivirus |
|||
LVP1177 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: APLP2, containing a RFP-Blasticidin dual selection marker. |
|||
h PCSK9 Expression Lentivirus |
|||
LVP1178 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: PCSK9, containing a RFP-Blasticidin dual selection marker. |
|||
h NTSR1 Expression Lentivirus |
|||
LVP1179 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: NTSR1, containing a RFP-Blasticidin dual selection marker. |
|||
pscAAV-MCS Expression Vector |
|||
VPK-430 | Cell Biolabs | 10 µg | 776.4 EUR |
Description: Clone your gene of interest into this AAV Expression Vector, then co-transfect along with AAV packaging vectors into a packaging host cell line such as 293AAV. |
|||
m CTAGA1 Expression Lentivirus |
|||
LVP916 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for mouse target: CTAGA1, containing a RFP-Blasticidin dual selection marker. |
|||
h SKIV2L Expression Lentivirus |
|||
LVP919 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: SKIV2L, containing a RFP-Blasticidin dual selection marker. |
|||
h SKIV2L Expression Lentivirus |
|||
LVP919-GP | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: SKIV2L, containing a GFP-Puromycin dual selection marker. |
|||
h TP5313 Expression Lentivirus |
|||
LVP926 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: TP5313, containing a RFP-Blasticidin dual selection marker. |
|||
h ELOVL5 Expression Lentivirus |
|||
LVP929 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: ELOVL5, containing a RFP-Blasticidin dual selection marker. |
|||
h MAGEA3 Expression Lentivirus |
|||
LVP1147 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: HDAC1, containing a RFP-Blasticidin dual selection marker. |
|||
h NANOS3 Expression Lentivirus |
|||
LVP1164 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: NANOS3, containing a RFP-Blasticidin dual selection marker. |
|||
h IL1RL1 Expression Lentivirus |
|||
LVP1168 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: IL1RL1, containing a RFP-Blasticidin dual selection marker. |
|||
h CTAG1B Expression Lentivirus |
|||
LVP1169 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: CTAG1B, containing a RFP-Blasticidin dual selection marker. |
|||
h MAGEA3 Expression Lentivirus |
|||
LVP1170 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: MAGEA3, containing a RFP-Blasticidin dual selection marker. |
|||
h COX7A1 Expression Lentivirus |
|||
LVP1173 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: COX7A1, containing a RFP-Blasticidin dual selection marker. |
|||
h BCL11B Expression Lentivirus |
|||
LVP1180 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: BCL11B, containing a RFP-Blasticidin dual selection marker. |
|||
pUC57-sgRNA expression vector |
|||
PVT18003 | Lifescience Market | 2 ug | 309.6 EUR |
H-Ras Expression Vector Set |
|||
STA-457 | Cell Biolabs | 1 kit | 1765.2 EUR |
Description: H-Ras Expression Vector Set contains 3 vectors: H-Ras wild type, T19N dominant negative mutant, and G12V constitutively active mutant. |
|||
ANPRA/Aequorin Expression vector |
|||
60641 | BPS Bioscience | 20 µg | 900 EUR |
Description: The ANPRA/Aequorin expression vector is designed to co-express human atrial natriuretic peptide receptor A (ANPRA, also called natriuretic peptide receptor A/guanylate cyclase A) and jellyfish (Aequorea victoria) Aequorin in mammalian cells. |
|||
h CEACAM5 Expression Lentivirus |
|||
LVP1153 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: CEACAM5, containing a RFP-Blasticidin dual selection marker. |
|||
h TNFSF11 Expression Lentivirus |
|||
LVP1157 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: TNFSF11, containing a RFP-Blasticidin dual selection marker. |
|||
BRAF, His-Tag (High Expression) |
|||
41237 | BPS Bioscience | 10 µg | 375 EUR |
Description: Human BRAF, also known as B-RAF1 and RAFB1, with 18 mutations to improve expression; S446A, S447A, I543A, I544S, I551K, Q562R, L588N, K630S, F667E, Y672S, A688R, L706S, Q709R, S713E, L716E, S720E, P722S, K723G. GenBank Accession #NM_004333, a.a. 444-723 with N-terminal His-tag, expressed in E. coli cells. MW = 33 kDa. |
|||
h TNFRSF1B Expression Lentivirus |
|||
LVP922 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: TNFRSF1B, containing a RFP-Blasticidin dual selection marker. |
|||
h KIAA1324 Expression Lentivirus |
|||
LVP1175 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: KIAA1324, containing a RFP-Blasticidin dual selection marker. |
|||
h KIAA0319L Expression Lentivirus |
|||
LVP920 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for human target: KIAA0319L, containing a RFP-Blasticidin dual selection marker. |
|||
GFP-Rac1 Expression Vector Set |
|||
STA-450 | Cell Biolabs | 1 kit | 1939.2 EUR |
Description: GFP-Rac1 Expression Vector Set contains 3 vectors: Rac wild type, T17N dominant negative mutant, and Q61L constitutively active mutant. Each vector also contains a GFP reporter sequence. |
|||
GFP-RhoA Expression Vector Set |
|||
STA-452 | Cell Biolabs | 1 kit | 1939.2 EUR |
Description: GFP-RhoA Expression Vector Set contains 3 vectors: RhoA wild type, T19N dominant negative mutant, and Q63L constitutively active mutant. Each vector also contains a GFP reporter sequence. |
|||
PhiC31 Integrase Expression Plasmid |
|||
FC200PA-1 | SBI | 10ug | 496 EUR |
GFP-Cdc42 Expression Vector Set |
|||
STA-451 | Cell Biolabs | 1 kit | 1939.2 EUR |
Description: GFP-Cdc42 Expression Vector Set contains 3 vectors: Cdc42 wild type, T17N dominant negative mutant, and Q61L constitutively active mutant. Each vector also contains a GFP reporter sequence. |
|||
Active Rac1 Expression Vector Set |
|||
STA-458 | Cell Biolabs | 1 kit | 1765.2 EUR |
Description: Active Rac1 Expression Vector Set contains 3 vectors expressing different constitutively active mutants of Rac1: Q61L, Q61L/F37A, and Q61L/Y40C. |
|||
pCMV-GFP-LC3 Expression Vector |
|||
CBA-401 | Cell Biolabs | 100 µL | 1243.2 EUR |
Description: Expression vector contains a fusion of GFP and LC3. A separate GFP control vector is also included. |
|||
h KRAS (G12D) Expression Lentivirus |
|||
LVP1166 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for a mutant (G12D) of human target: KRAS containing a RFP-Blasticidin dual selection marker. |
|||
Tet-on circRNA Expression Vector |
|||
PVT14643 | Lifescience Market | 2 ug | 843.6 EUR |
PinPoint Integrase Expression Plasmid |
|||
PIN200A-1 | SBI | 10ug | 688 EUR |
h TP53 (R175H) Expression Lentivirus |
|||
LVP1167 | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for a mutant R175H) of human target: TP53, containing a RFP-Blasticidin dual selection marker. |
|||
pAAV-IRES-Neo Expression Vector |
|||
VPK-416 | Cell Biolabs | 10 µg | 776.4 EUR |
Description: Clone your gene of interest into this AAV Expression Vector, then co-transfect along with AAV packaging vectors into a packaging host cell line such as 293AAV. |
|||
pAAV-IRES-GFP Expression Vector |
|||
VPK-418 | Cell Biolabs | 10 µg | 776.4 EUR |
Description: Clone your gene of interest into this AAV Expression Vector, then co-transfect along with AAV packaging vectors into a packaging host cell line such as 293AAV. |
|||
pAAV-IRES-Bsd Expression Vector |
|||
VPK-419 | Cell Biolabs | 10 µg | 776.4 EUR |
Description: Clone your gene of interest into this AAV Expression Vector, then co-transfect along with AAV packaging vectors into a packaging host cell line such as 293AAV. |
|||
pAAV-IRES-Puro Expression Vector |
|||
VPK-415 | Cell Biolabs | 10 µg | 776.4 EUR |
Description: Clone your gene of interest into this AAV Expression Vector, then co-transfect along with AAV packaging vectors into a packaging host cell line such as 293AAV. |
|||
pAAV-IRES-Hygro Expression Vector |
|||
VPK-417 | Cell Biolabs | 10 µg | 776.4 EUR |
Description: Clone your gene of interest into this AAV Expression Vector, then co-transfect along with AAV packaging vectors into a packaging host cell line such as 293AAV. |
|||
CEACAM5 CHO Cell Line (Low Expression) |
|||
78704-L | BPS Bioscience | 2 vials | 7150 EUR |
Description: Recombinant clonal CHO cell line stably expressing full-length human CEACAM5 (NM_004363). Surface expression of CEACAM5 was confirmed by flow cytometry. The stable clonal cell line was selected for different levels of CEACAM5 expression (High, Medium, and Low) compared to the parental CHO-K1 cell line. |
|||
Active H-Ras Expression Vector Set |
|||
STA-459 | Cell Biolabs | 1 kit | 1765.2 EUR |
Description: Active H-Ras Expression Vector Set contains 3 vectors expressing different constitutively active mutants of H-Ras: V12, V12S35, and V12C40. |
|||
CD36 HEK293 Cell Line (High Expression) |
|||
78526-H | BPS Bioscience | 2 vials | 7150 EUR |
Description: Recombinant clonal HEK293 cell line stably expressing full length human CD36. The stable clonal cell line was selected for medium and high levels of CD36 expression compared to the parental HEK293 cell line. |
|||
CEACAM5 CHO Cell Line (High Expression) |
|||
78704-H | BPS Bioscience | 2 vials | 7150 EUR |
Description: Recombinant clonal CHO cell line stably expressing full-length human CEACAM5 (NM_004363). Surface expression of CEACAM5 was confirmed by flow cytometry. The stable clonal cell line was selected for different levels of CEACAM5 expression (High, Medium, and Low) compared to the parental CHO-K1 cell line. |
|||
AAV-1 Helper Free Expression System |
|||
VPK-410-SER1 | Cell Biolabs | 1 kit | 1486.8 EUR |
Description: The AAV Helper Free System produces recombinant AAV containing your gene of interest without the need to use a helper adenovirus. The adenoviral genes required for proper AAV packaging are provided in the pHelper plasmid (E2A, E4 and VA RNA) or in the 293 packaging cells (E1). |
|||
AAV-2 Helper Free Expression System |
|||
VPK-410-SER2 | Cell Biolabs | 1 kit | 1486.8 EUR |
Description: The AAV Helper Free System produces recombinant AAV containing your gene of interest without the need to use a helper adenovirus. The adenoviral genes required for proper AAV packaging are provided in the pHelper plasmid (E2A, E4 and VA RNA) or in the 293 packaging cells (E1). |
|||
AAV-3 Helper Free Expression System |
|||
VPK-410-SER3 | Cell Biolabs | 1 kit | 1486.8 EUR |
Description: The AAV Helper Free System produces recombinant AAV containing your gene of interest without the need to use a helper adenovirus. The adenoviral genes required for proper AAV packaging are provided in the pHelper plasmid (E2A, E4 and VA RNA) or in the 293 packaging cells (E1). |
|||
AAV-4 Helper Free Expression System |
|||
VPK-410-SER4 | Cell Biolabs | 1 kit | 1486.8 EUR |
Description: The AAV Helper Free System produces recombinant AAV containing your gene of interest without the need to use a helper adenovirus. The adenoviral genes required for proper AAV packaging are provided in the pHelper plasmid (E2A, E4 and VA RNA) or in the 293 packaging cells (E1). |
|||
AAV-5 Helper Free Expression System |
|||
VPK-410-SER5 | Cell Biolabs | 1 kit | 1486.8 EUR |
Description: The AAV Helper Free System produces recombinant AAV containing your gene of interest without the need to use a helper adenovirus. The adenoviral genes required for proper AAV packaging are provided in the pHelper plasmid (E2A, E4 and VA RNA) or in the 293 packaging cells (E1). |
|||
AAV-6 Helper Free Expression System |
|||
VPK-410-SER6 | Cell Biolabs | 1 kit | 1486.8 EUR |
Description: The AAV Helper Free System produces recombinant AAV containing your gene of interest without the need to use a helper adenovirus. The adenoviral genes required for proper AAV packaging are provided in the pHelper plasmid (E2A, E4 and VA RNA) or in the 293 packaging cells (E1). |
|||
Gryphon Retroviral Expression System I |
|||
ABP-RVK-10001 | Allele Biotech | 1 set | Ask for price |
Description: PRODUCT LINE DISCONTINUED. Please contact us. |
|||
Gryphon Retroviral Expression System II |
|||
ABP-RVK-10002 | Allele Biotech | 1 set | Ask for price |
Description: PRODUCT LINE DISCONTINUED. Please contact us. |
|||
B7-H3 CHO Cell Line (Low Expression) |
|||
78541-L | BPS Bioscience | 2 vials | 7150 EUR |
Description: B7 homolog 3 protein (B7-H3) CHO Cell line is a recombinant clonal stable CHO cell line expressing full length human B7-H3 protein, also known as cluster of differentiation 276 (CD276, B7H3; B7RP-2; 4Ig-B7-H3). Surface expression of B7-H3 was confirmed by flow cytometry. Each stable clonal cell line was selected for High, Medium, or Low levels of B7-H3 expression to mimic different B7-H3 expression levels in various cancer types. |
|||
AAV-DJ Helper Free Expression System |
|||
VPK-410-DJ | Cell Biolabs | 1 kit | 1486.8 EUR |
Description: The AAV Helper Free System produces recombinant AAV containing your gene of interest without the need to use a helper adenovirus. The adenoviral genes required for proper AAV packaging are provided in the pHelper plasmid (E2A, E4 and VA RNA) or in the 293 packaging cells (E1). AAV Helper Free Complete Expression Systems are available for native serotypes 1 through 6, as well as the novel AAV-DJ and AAV-DJ/8. The AAV-DJ system provides a hybrid capsid created by DNA shuffling technology combining 8 different native serotypes: AAV-2, AAV-4, AAV-5, AAV-8, AAV-9, avian AAV, bovine AAV, and caprine AAV. The result is a highly infectious vector that can transduce a wide variety of cells and tissues at significantly higher rates than AAV-2. |
|||
B7-H3 CHO Cell Line (High Expression) |
|||
78541-H | BPS Bioscience | 2 vials | 7150 EUR |
Description: B7 homolog 3 protein (B7-H3) CHO Cell line is a recombinant clonal stable CHO cell line expressing full length human B7-H3 protein, also known as cluster of differentiation 276 (CD276, B7H3; B7RP-2; 4Ig-B7-H3). Surface expression of B7-H3 was confirmed by flow cytometry. Each stable clonal cell line was selected for High, Medium, or Low levels of B7-H3 expression to mimic different B7-H3 expression levels in various cancer types. |
|||
EP Reagent Biuret Reagent |
|||
1011601 | Scientific Laboratory Supplies | 1L | 52.8 EUR |
pRedPuro shRNA expression lentivector (EF1) |
|||
SI516A-1 | SBI | 10 ug | 594 EUR |
pAAV-MCS Promoterless Expression Vector |
|||
VPK-411 | Cell Biolabs | 10 µg | 776.4 EUR |
Description: Clone your gene of interest into this AAV Expression Vector, then co-transfect along with AAV packaging vectors into a packaging host cell line such as 293AAV. |
|||
pSMPUW-Neo Lentiviral Expression Vector |
|||
VPK-213 | Cell Biolabs | 10 µg | 748.8 EUR |
Description: Clone your gene of interest into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer. |
|||
CD36 HEK293 Cell Line (Medium Expression) |
|||
78526-M | BPS Bioscience | 2 vials | 7150 EUR |
Description: Recombinant clonal HEK293 cell line stably expressing full length human CD36. The stable clonal cell line was selected for medium and high levels of CD36 expression compared to the parental HEK293 cell line. |
|||
CEACAM5 CHO Cell Line (Medium Expression) |
|||
78704-M | BPS Bioscience | 2 vials | 7150 EUR |
Description: Recombinant clonal CHO cell line stably expressing full-length human CEACAM5 (NM_004363). Surface expression of CEACAM5 was confirmed by flow cytometry. The stable clonal cell line was selected for different levels of CEACAM5 expression (High, Medium, and Low) compared to the parental CHO-K1 cell line. |
|||
Human Myelin expression factor 2 (MYEF2) |
|||
1-CSB-EP015283HU | Cusabio |
|
|
Description: Recombinant Human Myelin expression factor 2(MYEF2),partial expressed in E.coli |
|||
scAAV-1 Helper Free Expression System |
|||
VPK-430-SER1 | Cell Biolabs | 1 kit | 1486.8 EUR |
Description: The AAV Helper Free System produces recombinant AAV containing your gene of interest without the need to use a helper adenovirus. The adenoviral genes required for proper AAV packaging are provided in the pHelper plasmid (E2A, E4 and VA RNA) or in the 293 packaging cells (E1). |
|||
scAAV-2 Helper Free Expression System |
|||
VPK-430-SER2 | Cell Biolabs | 1 kit | 1486.8 EUR |
Description: The AAV Helper Free System produces recombinant AAV containing your gene of interest without the need to use a helper adenovirus. The adenoviral genes required for proper AAV packaging are provided in the pHelper plasmid (E2A, E4 and VA RNA) or in the 293 packaging cells (E1). |
|||
scAAV-3 Helper Free Expression System |
|||
VPK-430-SER3 | Cell Biolabs | 1 kit | 1486.8 EUR |
Description: The AAV Helper Free System produces recombinant AAV containing your gene of interest without the need to use a helper adenovirus. The adenoviral genes required for proper AAV packaging are provided in the pHelper plasmid (E2A, E4 and VA RNA) or in the 293 packaging cells (E1). |
|||
scAAV-4 Helper Free Expression System |
|||
VPK-430-SER4 | Cell Biolabs | 1 kit | 1486.8 EUR |
Description: The AAV Helper Free System produces recombinant AAV containing your gene of interest without the need to use a helper adenovirus. The adenoviral genes required for proper AAV packaging are provided in the pHelper plasmid (E2A, E4 and VA RNA) or in the 293 packaging cells (E1). |
|||
scAAV-5 Helper Free Expression System |
|||
VPK-430-SER5 | Cell Biolabs | 1 kit | 1486.8 EUR |
Description: The AAV Helper Free System produces recombinant AAV containing your gene of interest without the need to use a helper adenovirus. The adenoviral genes required for proper AAV packaging are provided in the pHelper plasmid (E2A, E4 and VA RNA) or in the 293 packaging cells (E1). |
|||
scAAV-6 Helper Free Expression System |
|||
VPK-430-SER6 | Cell Biolabs | 1 kit | 1486.8 EUR |
Description: The AAV Helper Free System produces recombinant AAV containing your gene of interest without the need to use a helper adenovirus. The adenoviral genes required for proper AAV packaging are provided in the pHelper plasmid (E2A, E4 and VA RNA) or in the 293 packaging cells (E1). |
|||
pSMPUW-Puro Lentiviral Expression Vector |
|||
VPK-212 | Cell Biolabs | 10 µg | 748.8 EUR |
Description: Clone your gene of interest into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer. |
|||
Protein Limb Expression 1 (LIX1) Antibody |
|||
20-abx318393 | Abbexa |
|
|
Protein Limb Expression 1 (LIX1) Antibody |
|||
abx146234-100ug | Abbexa | 100 ug | 469.2 EUR |
Protein Limb Expression 1 (LIX1) Antibody |
|||
abx025913-400ul | Abbexa | 400 ul | 627.6 EUR |
Protein Limb Expression 1 (LIX1) Antibody |
|||
abx025913-80l | Abbexa | 80 µl | 343.2 EUR |
scAAV-DJ Helper Free Expression System |
|||
VPK-430-DJ | Cell Biolabs | 1 kit | 1486.8 EUR |
Description: The AAV Helper Free System produces recombinant AAV containing your gene of interest without the need to use a helper adenovirus. The adenoviral genes required for proper AAV packaging are provided in the pHelper plasmid (E2A, E4 and VA RNA) or in the 293 packaging cells (E1). AAV Helper Free Complete Expression Systems are available for native serotypes 1 through 6, as well as the novel AAV-DJ and AAV-DJ/8. The AAV-DJ system provides a hybrid capsid created by DNA shuffling technology combining 8 different native serotypes: AAV-2, AAV-4, AAV-5, AAV-8, AAV-9, avian AAV, bovine AAV, and caprine AAV. The result is a highly infectious vector that can transduce a wide variety of cells and tissues at significantly higher rates than AAV-2. |
|||
B7-H3 CHO Cell Line (Medium Expression) |
|||
78541-M | BPS Bioscience | 2 vials | 7150 EUR |
Description: B7 homolog 3 protein (B7-H3) CHO Cell line is a recombinant clonal stable CHO cell line expressing full length human B7-H3 protein, also known as cluster of differentiation 276 (CD276, B7H3; B7RP-2; 4Ig-B7-H3). Surface expression of B7-H3 was confirmed by flow cytometry. Each stable clonal cell line was selected for High, Medium, or Low levels of B7-H3 expression to mimic different B7-H3 expression levels in various cancer types. |
|||
Expression Negative Control Lentivirus (G418) |
|||
79902-G | BPS Bioscience | 500 µl x 2 | 795 EUR |
Description: The Expression Negative Control Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The controls package the same virus particles as the target expression virus, but they do not express a specific protein under the CMV promoter. _x000D_The Expression Negative Control Lentivirus (G418) expresses the gene for aminoglycoside 3' phosphotransferase, which confers resistance to kanamycin, neomycin, and geneticin (G418)._x000D_The Expression Negative Control Lentivirus (Hygromycin) expresses the gene for hygromycin B phosphotransferase, which confers resistance to Hygromycin._x000D_The Expression Negative Control Lentivirus (Puromycin) expresses the gene for puromycin N-acetyl-transferase, which confers resistance to puromycin._x000D_ _x000D_ |
|||
pGreenPuro shRNA expression lentivector (CMV) |
|||
SI505A-1 | SBI | 10 ug | 594 EUR |
pGreenPuro shRNA expression lentivector (EF1) |
|||
SI506A-1 | SBI | 10 ug | 594 EUR |
pSMPUW-Hygro Lentiviral Expression Vector |
|||
VPK-214 | Cell Biolabs | 10 µg | 748.8 EUR |
Description: Clone your gene of interest into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer. |
|||
RAPAd® RSV Adenoviral Expression System |
|||
VPK-251 | Cell Biolabs | 1 kit | 1243.2 EUR |
Description: Making an adenovirus with traditional recombinant methods takes 2-3 months and requires tedious plaque recombination. More recent technologies have shortened this time somewhat, but still produce relatively high amounts of wild type (replication-competent) plaques, levels of which increase with serial amplification. The RAPAd® Adenoviral Expression Systems produce recombinant adenovirus with substantially reduced wild-type virus, while considerably shortening the production time to 2-3 weeks. Serial amplification of adenovirus produced using the RAPAd® system does not significantly increase replication-competent adenovirus levels. The system uses a backbone vector from which the 5' ITR, packaging signal and E1 sequences have been removed. |
|||
RAPAd® CMV Adenoviral Expression System |
|||
VPK-252 | Cell Biolabs | 1 kit | 1243.2 EUR |
Description: Making an adenovirus with traditional recombinant methods takes 2-3 months and requires tedious plaque recombination. More recent technologies have shortened this time somewhat, but still produce relatively high amounts of wild type (replication-competent) plaques, levels of which increase with serial amplification. The RAPAd® Adenoviral Expression Systems produce recombinant adenovirus with substantially reduced wild-type virus, while considerably shortening the production time to 2-3 weeks. Serial amplification of adenovirus produced using the RAPAd® system does not significantly increase replication-competent adenovirus levels. The system uses a backbone vector from which the 5' ITR, packaging signal and E1 sequences have been removed. |
|||
Claudin-6 CHO Cell Line (Low Expression) |
|||
78527-L | BPS Bioscience | 2 vials | 7150 EUR |
Description: Recombinant clonal CHO cell line stably expressing full-length human claudin-6 (CLDN6 gene accession number NM_021195.5). Surface expression of claudin 6 was confirmed by flow cytometry. The stable clonal cell line was selected for high, medium, or low levels of claudin-6 expression compared to the parental CHO-K1 cell line. |
|||
EP Reagent Iodoplatinate Reagent |
|||
1046300 | Scientific Laboratory Supplies | 200ML | 446.4 EUR |
Myelin Expression Factor 2 (MYEF2) Antibody |
|||
abx235464-100ug | Abbexa | 100 ug | 577.2 EUR |
Myelin Expression Factor 2 (MYEF2) Antibody |
|||
20-abx109333 | Abbexa |
|
|
Myelin Expression Factor 2 (MYEF2) Antibody |
|||
20-abx113906 | Abbexa |
|
|
EP Reagent Molybdovanadic Reagent |
|||
1056700 | Scientific Laboratory Supplies | 100ML | 52.8 EUR |
Claudin-6 CHO Cell Line (High Expression) |
|||
78527-H | BPS Bioscience | 2 vials | 7150 EUR |
Description: Recombinant clonal CHO cell line stably expressing full-length human claudin-6 (CLDN6 gene accession number NM_021195.5). Surface expression of claudin 6 was confirmed by flow cytometry. The stable clonal cell line was selected for high, medium, or low levels of claudin-6 expression compared to the parental CHO-K1 cell line. |
|||
AAV-DJ/8 Helper Free Expression System |
|||
VPK-410-DJ-8 | Cell Biolabs | 1 kit | 1486.8 EUR |
Description: The AAV Helper Free System produces recombinant AAV containing your gene of interest without the need to use a helper adenovirus. The adenoviral genes required for proper AAV packaging are provided in the pHelper plasmid (E2A, E4 and VA RNA) or in the 293 packaging cells (E1). AAV Helper Free Complete Expression Systems are available for native serotypes 1 through 6, as well as the novel AAV-DJ and AAV-DJ/8. The AAV-DJ system provides a hybrid capsid created by DNA shuffling technology combining 8 different native serotypes: AAV-2, AAV-4, AAV-5, AAV-8, AAV-9, avian AAV, bovine AAV, and caprine AAV. The result is a highly infectious vector that can transduce a wide variety of cells and tissues at significantly higher rates than AAV-2. AAV-DJ/8 was created by making a point mutation in the heparin binding domain of AAV-DJ. Recombinant AAV produced from the AAV-DJ/8 system closely resembles AAV-8 and AAV-9 in its ability to infect heart and brain tissues. |
|||
CD7 CHO Cell Line (Medium or High Expression)-78324-H |
|||
78324-H | BPS Bioscience | 2 vials | 7150 EUR |
Description: Recombinant CD7 CHO-K1 cell lines expressing full-length human CD7 receptor (accession number: NM_006137.6). Surface expression of human CD7 was confirmed by flow cytometry. Each stable clonal cell line was selected for high or medium levels of CD7 expression to mimic different stages of cancer target cells with various CD7 expression levels. |
|||
CD7 CHO Cell Line (Medium or High Expression)-78324-M |
|||
78324-M | BPS Bioscience | 2 vials | 7150 EUR |
Description: Recombinant CD7 CHO-K1 cell lines expressing full-length human CD7 receptor (accession number: NM_006137.6). Surface expression of human CD7 was confirmed by flow cytometry. Each stable clonal cell line was selected for high or medium levels of CD7 expression to mimic different stages of cancer target cells with various CD7 expression levels. |
|||
Baculovirus expression vector pAc-g-CH3 |
|||
30R-AB001 | Fitzgerald | 5 ug | 739.2 EUR |
Description: Baculovirus cassette vector pAc-l-CH3 for the expression of human, humanized or chimeric IgG(lambda) in insect cells and secretion of assembled antibodies into the supernatant. |
|||
Genorise® Chicken CCL7 Expression Plasmid |
|||
GR148007 | Genorise Scientific | 10 µg | 219 EUR |
RAPAd® miRNA Adenoviral Expression System |
|||
VPK-253 | Cell Biolabs | 1 kit | 1243.2 EUR |
Description: Making an adenovirus with traditional recombinant methods takes 2-3 months and requires tedious plaque recombination. More recent technologies have shortened this time somewhat, but still produce relatively high amounts of wild type (replication-competent) plaques, levels of which increase with serial amplification. The RAPAd® Adenoviral Expression Systems produce recombinant adenovirus with substantially reduced wild-type virus, while considerably shortening the production time to 2-3 weeks. Serial amplification of adenovirus produced using the RAPAd® system does not significantly increase replication-competent adenovirus levels. The system uses a backbone vector from which the 5' ITR, packaging signal and E1 sequences have been removed. |
|||
CD95 CHO Cell Line (Medium or High Expression)-78499-H |
|||
78499-H | BPS Bioscience | 2 vials | 7150 EUR |
Description: The CD95 CHO cell line is a recombinant clonal stable CHO cell line constitutively expressing full-length human CD95 receptor (accession number: NM_000043.3). Surface expression of human CD95 was confirmed by flow cytometry. Each clonal cell line was selected for different levels of CD95 expression (High or Medium) to mimic varying CD95 expression levels in cancer cells. |
|||
CD95 CHO Cell Line (Medium or High Expression)-78499-M |
|||
78499-M | BPS Bioscience | 2 vials | 7150 EUR |
Description: The CD95 CHO cell line is a recombinant clonal stable CHO cell line constitutively expressing full-length human CD95 receptor (accession number: NM_000043.3). Surface expression of human CD95 was confirmed by flow cytometry. Each clonal cell line was selected for different levels of CD95 expression (High or Medium) to mimic varying CD95 expression levels in cancer cells. |
|||
pC001 - huLshC2C2- MBP for bacterial expression |
|||
PVT10645 | Lifescience Market | 2 ug | 361.2 EUR |
Exoenzyme C3 (Rho Inhibitor) Expression Vector |
|||
STA-460 | Cell Biolabs | 1 kit | 860.4 EUR |
Description: This mammalian expression vector codes for Exoenzyme C3, a Rho inhibitor. |
|||
Claudin-6 CHO Cell Line (Medium Expression) |
|||
78527-M | BPS Bioscience | 2 vials | 7150 EUR |
Description: Recombinant clonal CHO cell line stably expressing full-length human claudin-6 (CLDN6 gene accession number NM_021195.5). Surface expression of claudin 6 was confirmed by flow cytometry. The stable clonal cell line was selected for high, medium, or low levels of claudin-6 expression compared to the parental CHO-K1 cell line. |
|||
scAAV-DJ/8 Helper Free Expression System |
|||
VPK-430-DJ-8 | Cell Biolabs | 1 kit | 1486.8 EUR |
Description: The AAV Helper Free System produces recombinant AAV containing your gene of interest without the need to use a helper adenovirus. The adenoviral genes required for proper AAV packaging are provided in the pHelper plasmid (E2A, E4 and VA RNA) or in the 293 packaging cells (E1). AAV Helper Free Complete Expression Systems are available for native serotypes 1 through 6, as well as the novel AAV-DJ and AAV-DJ/8. The AAV-DJ system provides a hybrid capsid created by DNA shuffling technology combining 8 different native serotypes: AAV-2, AAV-4, AAV-5, AAV-8, AAV-9, avian AAV, bovine AAV, and caprine AAV. The result is a highly infectious vector that can transduce a wide variety of cells and tissues at significantly higher rates than AAV-2. AAV-DJ/8 was created by making a point mutation in the heparin binding domain of AAV-DJ. Recombinant AAV produced from the AAV-DJ/8 system closely resembles AAV-8 and AAV-9 in its ability to infect heart and brain tissues. |
|||
Platinum Retroviral Expression System, Ecotropic |
|||
VPK-300 | Cell Biolabs | 1 kit | 1402.8 EUR |
Description: Retroviral vectors are useful for delivering genes of interest into a target cells where integration into the genome is desired. However, traditional retroviral expression technologies result in low viral titers, making gene expression studies challenging. Platinum Retroviral Expression Systems incorporate superior packaging cell lines and vector technologies to produce high-titer virus with a single plasmid transfection. This system includes our exclusive Platinum-E Packaging cell line, which contains the gag and pol genes and an ecotropic envelope protein for viral packaging. Simply clone your gene of interest into the vector provided and transfect into the packaging cells. |
|||
Platinum Retroviral Expression System, Pantropic |
|||
VPK-302 | Cell Biolabs | 1 kit | 1402.8 EUR |
Description: Retroviral vectors are useful for delivering genes of interest into a target cells where integration into the genome is desired. However, traditional retroviral expression technologies result in low viral titers, making gene expression studies challenging. Platinum Retroviral Expression Systems incorporate superior packaging cell lines and vector technologies to produce high-titer virus with a single plasmid transfection. This system includes our exclusive Platinum-GP Packaging cell line which contains the gag and pol genes necessary for viral packaging. Simply clone your gene of interest into the vector provided and co-transfect into the packaging cells along with the included VSVG plasmid. |
|||
EP Reagent Methoxyphenylacetic Reagent |
|||
1053601 | Scientific Laboratory Supplies | 100ML | 435.6 EUR |
Cre Recombinase Expression Plasmid (pCMV-CRE) |
|||
CRE100A-1 | SBI | 10 µg | 412 EUR |
Flp recombinase expression HEK293 stable cell |
|||
SC006 | GenTarget | 2 x 106 cell/ml x 1ml | 2670 EUR |
Description: Flp recombinase stable cell line with Blasticidin resistance |
|||
Protein Limb Expression 1 (LIX1) Antibody (HRP) |
|||
20-abx308975 | Abbexa |
|
|
Expression Negative Control Lentivirus (Puromycin) |
|||
79902-P | BPS Bioscience | 500 µl x 2 | 795 EUR |
Description: The Expression Negative Control Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The controls package the same virus particles as the target expression virus, but they do not express a specific protein under the CMV promoter. _x000D_The Expression Negative Control Lentivirus (G418) expresses the gene for aminoglycoside 3' phosphotransferase, which confers resistance to kanamycin, neomycin, and geneticin (G418)._x000D_The Expression Negative Control Lentivirus (Hygromycin) expresses the gene for hygromycin B phosphotransferase, which confers resistance to Hygromycin._x000D_The Expression Negative Control Lentivirus (Puromycin) expresses the gene for puromycin N-acetyl-transferase, which confers resistance to puromycin._x000D_ _x000D_ |
|||
EP Reagent Phosphomolybdotungstic Reagent |
|||
1065000 | Scientific Laboratory Supplies | 100ML | 201.6 EUR |
BCMA CHO Recombinant Cell Line (Low Expression) |
|||
79500-L | BPS Bioscience | 2 vials | 6500 EUR |
Description: Recombinant clonal stable CHO cell line constitutively expressing full length human BCMA protein, also known as TNFRSF17, (Genbank #NM_001192). Surface expression of BCMA was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of BCMA expression, (H. M, L), to mimic different stages of cancer target cells with various BCMA expression levels. |
|||
CD19 CHO Recombinant Cell Line (Low Expression) |
|||
79561-L | BPS Bioscience | 2 vials | 7150 EUR |
Description: Recombinant clonal stable CHO cell line constitutively expressing full length human CD19 protein, also known as B4 or CVID3, (Genbank #NM_001770). Surface expression of CD19 was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of CD19 expression (High, Medium, Low) to mimic different stages of cancer target cells with various CD19 expression levels. |
|||
CD37/CHO Recombinant Cell Line (Low Expression) |
|||
79607-L | BPS Bioscience | 2 vials | 6500 EUR |
Description: Recombinant clonal stable CHO cell line constitutively expressing full length human CD37 protein, also known as GP52-40; TSPAN26; leukocyte antigen CD37 (Genbank #NM_001774). Surface expression of CD37 was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of CD37 expression, (High, Medium, Low), to mimic different stages of cancer target cells with various CD37 expression levels. |
|||
CD38 CHO Recombinant Cell Line (Low Expression) |
|||
79615-L | BPS Bioscience | 2 vials | 7150 EUR |
Description: Recombinant clonal stable CHO cell line constitutively expressing full length human CD20 protein, also known as MS4A1 (Genbank #NM_152866). Surface expression of CD20 was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of CD20 expression (High, Medium) to mimic different stages of cancer target cells with various CD20 expression levels. |
|||
Protein Limb Expression 1 (LIX1) Antibody (FITC) |
|||
20-abx308976 | Abbexa |
|
|
Genorise® Feline EGF Expression Plasmid DNA |
|||
GR233001 | Genorise Scientific | 10 µg | 199 EUR |
Genorise® Chicken IL-6 Expression Plasmid |
|||
GR148001 | Genorise Scientific | 10 µg | 219 EUR |
Genorise® Chicken IL-4 Expression Plasmid |
|||
GR148003 | Genorise Scientific | 10 µg | 219 EUR |
Expression Negative Control Lentivirus (Hygromycin) |
|||
79902-H | BPS Bioscience | 500 µl x 2 | 795 EUR |
Description: The Expression Negative Control Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The controls package the same virus particles as the target expression virus, but they do not express a specific protein under the CMV promoter. _x000D_The Expression Negative Control Lentivirus (G418) expresses the gene for aminoglycoside 3' phosphotransferase, which confers resistance to kanamycin, neomycin, and geneticin (G418)._x000D_The Expression Negative Control Lentivirus (Hygromycin) expresses the gene for hygromycin B phosphotransferase, which confers resistance to Hygromycin._x000D_The Expression Negative Control Lentivirus (Puromycin) expresses the gene for puromycin N-acetyl-transferase, which confers resistance to puromycin._x000D_ _x000D_ |
|||
Platinum Retroviral Expression System, Amphotropic |
|||
VPK-301 | Cell Biolabs | 1 kit | 1402.8 EUR |
Description: Retroviral vectors are useful for delivering genes of interest into a target cells where integration into the genome is desired. However, traditional retroviral expression technologies result in low viral titers, making gene expression studies challenging. Platinum Retroviral Expression Systems incorporate superior packaging cell lines and vector technologies to produce high-titer virus with a single plasmid transfection. This system includes our exclusive Platinum-A Packaging cell line, which contains the gag and pol genes and an amphotropic envelope protein for viral packaging. Simply clone your gene of interest into the vector provided and transfect into the packaging cells. |
|||
Myelin expression factor 2 Polyclonal Antibody |
|||
42263-100ul | SAB | 100ul | 399.6 EUR |
pSMPUW-GFP-LC3 Lentiviral Expression Vector |
|||
LTV-801 | Cell Biolabs | 10 µg | 1444.8 EUR |
Description: Expression vector contains a fusion of GFP and LC3. A separate GFP control vector is also included. |
|||
RAPAd® Universal Adenoviral Expression System |
|||
VPK-250 | Cell Biolabs | 1 kit | 1243.2 EUR |
Description: Making an adenovirus with traditional recombinant methods takes 2-3 months and requires tedious plaque recombination. More recent technologies have shortened this time somewhat, but still produce relatively high amounts of wild type (replication-competent) plaques, levels of which increase with serial amplification. The RAPAd® Adenoviral Expression Systems produce recombinant adenovirus with substantially reduced wild-type virus, while considerably shortening the production time to 2-3 weeks. Serial amplification of adenovirus produced using the RAPAd® system does not significantly increase replication-competent adenovirus levels. The system uses a backbone vector from which the 5' ITR, packaging signal and E1 sequences have been removed. The RAPAd® Universal Adenoviral Expression System (# VPK-250) contains a promoterless shuttle vector to allow you to insert the promoter of your choice along with your gene of interest to maximize gene expression. |
|||
EP Reagent Sulfomolybdic Reagent R3 |
|||
1086500 | Scientific Laboratory Supplies | 1L | 354 EUR |
BCMA CHO Recombinant Cell Line (High Expression) |
|||
79500-H | BPS Bioscience | 2 vials | 6500 EUR |
Description: Recombinant clonal stable CHO cell line constitutively expressing full length human BCMA protein, also known as TNFRSF17, (Genbank #NM_001192). Surface expression of BCMA was confirmed by flow cytometry. |
|||
CD22 CHO Recombinant Cell Line (High Expression) |
|||
79557-H | BPS Bioscience | 2 vials | 7150 EUR |
Description: Recombinant clonal stable CHO cell line constitutively expressing full length human CD22 protein (Genbank #NM_001771). Surface expression of CD22 was confirmed by flow cytometry. This clonal cell line was selected for medium level expression of CD22. A clone exhibiting higher levels of CD22 expression is also available (#79557-M). Please contact BPS Bioscience for additional information. |
|||
CD19 CHO Recombinant Cell Line (High Expression) |
|||
79561-H | BPS Bioscience | 2 vials | 7150 EUR |
Description: Recombinant clonal stable CHO cell line constitutively expressing full length human CD19 protein, also known as B4 or CVID3, (Genbank #NM_001770). Surface expression of CD19 was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of CD19 expression (High, Medium, Low) to mimic different stages of cancer target cells with various CD19 expression levels. |
|||
CD37/CHO Recombinant Cell Line (High Expression) |
|||
79607-H | BPS Bioscience | 2 vials | 6500 EUR |
Description: Recombinant clonal stable CHO cell line constitutively expressing full length human CD37 protein, also known as GP52-40; TSPAN26; leukocyte antigen CD37 (Genbank #NM_001774). Surface expression of CD37 was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of CD37 expression, (High, Medium, Low), to mimic different stages of cancer target cells with various CD37 expression levels. |
|||
CD38 CHO Recombinant Cell Line (High Expression) |
|||
79615-H | BPS Bioscience | 2 vials | 7150 EUR |
Description: Recombinant clonal stable CHO cell line constitutively expressing full length human CD20 protein, also known as MS4A1 (Genbank #NM_152866). Surface expression of CD20 was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of CD20 expression (High, Medium) to mimic different stages of cancer target cells with various CD20 expression levels. |
|||
CD20 CHO Recombinant Cell Line (High Expression) |
|||
79624-H | BPS Bioscience | 2 vials | 7150 EUR |
Description: Recombinant clonal stable CHO cell line constitutively expressing full length human CD20 protein, also known as MS4A1 (Genbank #NM_152866). Surface expression of CD20 was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of CD20 expression (High, Medium) to mimic different stages of cancer target cells with various CD20 expression levels. |
|||
Myelin Expression Factor 2 (MYEF2) Antibody (HRP) |
|||
20-abx108522 | Abbexa |
|
|
PD-L1 / TCR Activator Mammalian Expression Kit |
|||
60610 | BPS Bioscience | 500 rxns. | 590 EUR |
Description: The recombinant expression vectors are designed to express human engineered T cell receptor (TCR) activator and human PD-L1 (GenBank Accession #NM_014143) in mammalian cells. The transfected cells can be used in conjunction with PD-1/NFAT Reporter/Jurkat T cells (BPS #60535) to study the interactions of PD-1 with PD-L1 ligand in a cellular context and screen for modulators of this signaling pathway._x000D_In this assay, PD-1/NFAT Reporter/Jurkat T cells are used as effector cells; HEK293 cells overexpressing PD-L1 (or PD-L2) and an engineered T cell receptor (TCR) activator are used as target cells. When these two cells are co-cultivated, TCR complexes on effector cells are activated by TCR activator on target cells, resulting in expression of the NFAT luciferase reporter. However, PD1 and PD-L1 (or PD-L2) ligation prevents TCR activation and suppresses the NFAT-responsive luciferase activity. This inhibition can be specifically reversed by anti-PD1 or anti-PD-L1 antibodies. PD1/PD-L1 neutralizing antibodies block PD1:PD-L1 interaction and promote T cell activation, resulting in reactivation of the NFAT responsive luciferase reporter. |
|||
PD-L2 / TCR Activator Mammalian Expression Kit |
|||
60620 | BPS Bioscience | 500 rxns. | 565 EUR |
Description: The recombinant expression vectors are designed to express human engineered T cell receptor (TCR) activator and human PD-L2 (GenBank Accession #NM_025239) in mammalian cells. The transfected cells can be used in conjunction with PD-1/NFAT Reporter/Jurkat T cells (BPS #60535) to study the interactions of PD-1 with PD-L2 ligand in a cellular context and screen for modulators of this signaling pathway._x000D_In this assay, PD-1/NFAT Reporter/Jurkat T cells are used as effector cells; HEK293 cells overexpressing PD-L1 (or PD-L2) and an engineered T cell receptor (TCR) activator are used as target cells. When these two cells are co-cultivated, TCR complexes on effector cells are activated by TCR activator on target cells, resulting in expression of the NFAT luciferase reporter. However, PD1 and PD-L1 or PD-L2 ligation prevents TCR activation and suppresses the NFAT-responsive luciferase activity. This inhibition can be specifically reversed by anti-PD1 or anti-PD-L1 antibodies. PD1, PD-L1, or PD-L2 neutralizing antibodies block PD1:PD-L1 and/or PD1:PD-L2 interaction and promote T cell activation, resulting in reactivation of the NFAT responsive luciferase reporter. |
|||
h INS-IGF2 (GFP-Puro) Expression Lentivirus |
|||
LVP699-GP | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for expressing human target: INS-IGF2 ( INS-IGF2 readthrough). It also contains a GFP-Puromycin dual selection marker. |
No important correlation was discovered between the aggregative and biophysical properties, reminiscent of hydrophobicity, contents of intrinsically disordered areas, and expression ranges, of CTAs.